Scientists searching for platinum anticancer drugs claim to have to have discovered a compound that accumulates in cells more readily than commonly used colorectal cancer drugs.

This could mean that the drug might be useful in treating colorectal tumours with fewer side effects.

Research from MIT found that a compound known as cDPCP may target colorectal cells specifically, which would save other tissues from harm.

Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT and senior author of the paper, said: "This compound, the antitumor properties of which were established in mice over 20 years ago, emerged in our search for platinum anticancer drug candidates with cellular uptake properties analogous or superior to those of oxaliplatin."

A clinical trial is yet to be launched in humans but because oxaliplatin and cisplatin enter almost every cell causing side effects, cDPCP requires the assistance of organic cation transporters in the cell membrane.

The cDPCP then engages with colorectal cells through the assistance of OCT1 and OCT2.



Source:

MIT researchers see alternative to common colorectal cancer drug, 17/06/08
http://www.eurekalert.org/pub_releases/2008-06/miot-mrs061708.php